Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/179973
Title: Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study
Author: Jantus-lewintre, Eloisa
Massutí Sureda, Bartomeu
González Larriba, José Luis
Rodríguez-abreu, Delvys
Juan, Oscar
Blasco, Ana
Dómine, Manuel
Provencio Pulla, Mariano
Garde, Javier
Álvarez, Rosa
Maestu, Inmaculada
Pérez De Carrión, Ramón
Artal, Ángel
Rolfo, Christian
De Castro, Javier
Guillot, Mónica
Oramas, Juana
De Las Peñas, Ramón
Ferrera, Lioba
Martínez, Natividad
Serra, Òlbia
Rosell, Rafael
Camps, Carlos
Issue Date: 26-Jul-2021
Publisher: Frontiers Media SA
Abstract: Finding angiogenic prognostic markers in advanced non-small-cell lung cancer is still an unmet medical need. We explored a set of genetic variants in the VEGF-pathway as potential biomarkers to predict clinical outcomes of patients with non-small-cell lung cancer treated with chemotherapy plus bevacizumab. We prospectively analyzed the relationship between VEGF-pathway components with both pathological and prognostic variables in response to chemotherapy plus bevacizumab in 168 patients with non-squamous non-small-cell lung cancer. Circulating levels of VEGF and VEGFR2 and expression of specific endothelial surface markers and single-nucleotide polymorphisms in VEGF-pathway genes were analyzed. The primary clinical endpoint was progression-free survival. Secondary endpoints included overall survival and objective tumor response. VEGFR-1 rs9582036 variants AA/AC were associated with increased progression-free survival (p = 0.012 and p = 0.035, respectively), and with improved overall survival (p = 0.019) with respect to CC allele. Patients with VEGF-A rs3025039 harboring allele TT had also reduced mortality risk (p = 0.049) compared with the CC allele. The VEGF-A rs833061 variant was found to be related with response to treatment, with 61.1% of patients harboring the CC allele achieving partial treatment response. High pre-treatment circulating levels of VEGF-A were associated with shorter progression-free survival (p = 0.036). In conclusion, in this prospective study, genetic variants in VEGFR-1 and VEGF-A and plasma levels of VEGF-A were associated with clinical benefit, progression-free survival, or overall survival in a cohort of advanced non-squamous non-small-cell lung cancer patients receiving chemotherapy plus antiangiogenic therapy.
Note: Reproducció del document publicat a: https://doi.org/10.3389/fonc.2021.695038
It is part of: Frontiers in Oncology, 2021, vol. 11
URI: http://hdl.handle.net/2445/179973
Related resource: https://doi.org/10.3389/fonc.2021.695038
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
fonc-11-695038.pdf1.09 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.